This pharmacogenetics study identified deleterious point mutations in the genes encoding CYP3A4/5 enzymes involved in the metabolism of FDA/EMA-approved COVID-19 antiviral drugs, remdesivir, nirmatrelvir/ritonavir. Here, CYP3A4 is linked to COVID-19.